These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32167070)

  • 1. The efficacy of measles-mumps-rubella vaccine versus salicylic acid-lactic paint in the treatment of warts.
    Deshmukh AR; Nawale SS; Patil SS; Pawar SS
    Indian J Dermatol Venereol Leprol; 2020; 86(6):753. PubMed ID: 32167070
    [No Abstract]   [Full Text] [Related]  

  • 2. Intralesional mumps, measles and rubella vaccine in the treatment of cutaneous warts.
    Saini P; Mittal A; Gupta LK; Khare AK; Mehta S
    Indian J Dermatol Venereol Leprol; 2016; 82(3):343-5. PubMed ID: 27088951
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy using topical measles, mumps and rubella vaccine for treatment of verruca plana.
    Mohta A; Kushwaha RK; Gautam U; Jain SK
    Indian J Dermatol Venereol Leprol; 2021; 87(2):285-287. PubMed ID: 33769758
    [No Abstract]   [Full Text] [Related]  

  • 4. Measles, mumps, and rubella vaccine: a new option to treat common warts?
    Iorizzo M; Marazza G
    Int J Dermatol; 2014 Apr; 53(4):e243-5. PubMed ID: 23786798
    [No Abstract]   [Full Text] [Related]  

  • 5. Intralesional measles, mumps, and rubella vaccine after failure of intralesional Candida antigen for the treatment of recalcitrant pediatric warts.
    Ulschmid CM; Patel J; Pan AY; Liegl M; Holland KE
    Pediatr Dermatol; 2023; 40(6):1057-1059. PubMed ID: 37596908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of the efficacy and safety of intralesional measles, mumps, and rubella vaccine versus intralesional vitamin D3 for the treatment of warts in children.
    Mohta A; Kushwaha RK; Gautam U; Sharma P; Nyati A; Jain SK
    Pediatr Dermatol; 2020 Sep; 37(5):853-859. PubMed ID: 32681688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralesional tuberculin (PPD) versus measles, mumps, rubella (MMR) vaccine in treatment of multiple warts: a comparative clinical and immunological study.
    Shaheen MA; Salem SA; Fouad DA; El-Fatah AA
    Dermatol Ther; 2015; 28(4):194-200. PubMed ID: 25847793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of anogenital warts with measles, mumps, and rubella vaccine.
    Kansal NK
    Dermatol Ther; 2020 Nov; 33(6):e13987. PubMed ID: 32638481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Difficult-to-Treat Warts: Traditional and New Approaches.
    Friedman PC
    Am J Clin Dermatol; 2021 May; 22(3):379-394. PubMed ID: 33432476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of recalcitrant warts with intralesional measles, mumps, and rubella vaccine: a promising approach.
    Nofal A; Nofal E; Yosef A; Nofal H
    Int J Dermatol; 2015 Jun; 54(6):667-71. PubMed ID: 25070525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year experience of using the measles, mumps and rubella vaccine as intralesional immunotherapy for warts.
    Na CH; Choi H; Song SH; Kim MS; Shin BS
    Clin Exp Dermatol; 2014 Jul; 39(5):583-9. PubMed ID: 24934912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intralesional immunotherapy of common warts: successful treatment with mumps, measles and rubella vaccine.
    Nofal A; Nofal E
    J Eur Acad Dermatol Venereol; 2010 Oct; 24(10):1166-70. PubMed ID: 20202055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local and distal involution of recalcitrant warts after a single intralesional dose of measles, mumps, and rubella vaccine.
    Cantor AS; Hardy CL
    Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mumps, Measles, and Rubella Vaccine for the Treatment of a Recalcitrant Subungual Wart.
    Morales-Raya C; Maroñas-Jiménez L; Aragón-Miguel R; Postigo-Llorente C
    Actas Dermosifiliogr; 2017 Dec; 108(10):966-968. PubMed ID: 28709617
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative study of intralesional tuberculin protein purified derivative (PPD) and intralesional measles, mumps, rubella (MMR) vaccine for multiple resistant warts.
    Mohammed YF; Ibrahim HS; Elbarbary MA; Elsaie ML
    J Cosmet Dermatol; 2021 Mar; 20(3):868-874. PubMed ID: 33118675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR.
    Diaz-Ortega JL; Bennett JV; Castaneda D; Vieyra JR; Valdespino-Gomez JL; de Castro JF
    Vaccine; 2010 Jan; 28(3):692-8. PubMed ID: 19861187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
    LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P
    Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapies of oral retinoid and topical salicylic acid in recalcitrant pigmented warts of a child.
    Tsukahara R; Miyata K; Go U; Mitsuishi T
    J Dermatol; 2020 May; 47(5):e203-e204. PubMed ID: 32141107
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey.
    Amela C; Pachón I; de Ory F
    Eur J Epidemiol; 2003; 18(1):71-9. PubMed ID: 12705626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.